Merck’s Vioxx Successor Arcoxia May Be Closer To Market
FDA will need to weigh issues related to hypertension and length of the studies after preliminary results of massive trials show comparable cardiovascular events for etoricoxib and diclofenac.
FDA will need to weigh issues related to hypertension and length of the studies after preliminary results of massive trials show comparable cardiovascular events for etoricoxib and diclofenac.